Dynavax to Present New Data for SD-101 in Combination with

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
163
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting

Abstract Data Show Overall Response Rate of 60% in 25 Advanced Melanoma Patients Naïve to Anti-PD-1 Therapy

Poster Presentation to Include Data from a Total of over 50 Patients and Will Compare SD-101 at Two Dose Levels

BERKELEY, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (NASDAQ: DVAX ) announced today that data will be presented from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA ® (pembrolizumab), an anti-PD-1 therapy developed by Merck (known as MSD outside the United States and Canada).  Data on patients with advanced melanoma who are naïve to anti-PD-1 therapy is the subject of a poster presentation and will be highlighted in a poster discussion session at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2018 in Chicago, IL.

The abstract for the poster titled “Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD1 therapy” has been posted on the 2018 ASCO Annual Meeting website, here . The abstract summarizes efficacy data on 25 patients that were available at the time of abstract submission in early February and shows an overall response rate (ORR) of 60%.  The combination reported low rates of Grade 3-4 treatment-related adverse events and no evidence of an increased rate of immune-related adverse events. The poster at ASCO in June will present efficacy data from over 50 patients comparing two doses of SD-101, 2mg in 1-4 lesions versus 8mg in a single lesion.

The details of the poster presentation and discussion session are as follows:

Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy

    Session Title: Melanoma/Skin Cancers
    Abstract: 9513
    Poster Board: 340
    Poster Session Date/Time: Monday, June 4, 2018, 1:15 PM - 4:45 PM CDT
    Poster Session Location: McCormick Place South, Hall A, Advanced Disease Poster Section
    Discussion Session Date/Time: Monday, June 4, 2018, 4:45 PM - 6:00 PM CDT
    Discussion Session Location: McCormick Place Lakeside Center, Level 4 - E451
     

About MEL-01 (KEYNOTE-184) The dose-escalation and expansion study of SD-101 in combination with KEYTRUDA includes patients with histologically or cytologically confirmed unresectable Stage IIIC/IV melanoma. The primary endpoints of the trial are safety and preliminary efficacy of intratumoral SD-101 in combination with KEYTRUDA. In addition, biomarkers are being evaluated.

About SD-101 SD-101, the Company's lead clinical candidate, is a proprietary, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide. Dynavax is evaluating this intratumoral TLR9 agonist in several clinical studies to assess its safety and activity, including a Phase 2 study in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy, in patients with advanced melanoma and in patients with head and neck squamous cell cancer, in a clinical collaboration with Merck. Dynavax maintains all commercial rights to SD-101.

About Dynavax Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com .

Forward Looking Statement This press release contains "forward-looking" statements, including statements regarding the conduct of clinical trials of SD-101. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether we can timely provide adequate clinical supplies; initiation, enrollment and completion of clinical trials of SD-101; the results of clinical trials and the impact of those results on the initiation or continuation of subsequent trials and issues arising in the regulatory process; the ability to successfully develop and commercialize SD-101; and whether or not Dynavax and parties with whom we are collaborating may reach any future agreement on further studies or a more extensive collaboration beyond the clinical trials contemplated under the existing agreements, as well as other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

       
Contact: David Burke Director, IR & Corporate Communications 510.665.7269 dburke@dynavax.com     Media Contact: Rachel St. Martin W2O wcg 646.894.5757 rstmartin@w2ogroup.com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 132

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf

Updated Category News Views 67

Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...

Continue Reading
Texas Plumbing Award Signals Local Service Discipline

Updated Category News Views 99

A clogged main line is not glamorous, but it is where a local service reputation gets tested for real. Neighborhood Plumbing and Drain has been named a 2026 Best of Texas Award winner in the Plumbing Contractors category, a recognition that matters less as a trophy than as a public signal: customers around Central Texas have noticed the outfit. For anyone watching the...

Continue Reading
TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 106

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 106

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 196

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
Illumina's Virtual Cell Win Raises Bigger AI Stakes

Updated Category News Views 97

A blind prediction contest is a useful place to separate glossy AI talk from actual biology. Illumina's BioInsight AI Lab took first place in Arc Institute's 2026 Virtual Cell Challenge, outperforming roughly 1,500 competitors on predictions of how cells would react when genes were knocked down. That is not a quarterly revenue number, and nobody should pretend otherwise....

Continue Reading
COP31 Puts China’s Weather-to-Energy Model on View

Updated Category News Views 55

Storm maps are becoming operating manuals, and that is the hard reality behind a November 13 COP31 event in Antalya, Türkiye. The session, “From Early Warning to Energy Action: Pathways for Global Climate Diplomacy and Cooperation,” put China’s effort to tie meteorological intelligence to energy-system decisions under an international spotlight. This is not...

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 27

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
"btn" href="https://investorshangout.com/blog/news?page=2">More News Articles